The Institute for Clinical and Economic Review (ICER) in a recently-released document outlines its planned review of high cholesterol treatments.
ICER’s assessment will include Novartis’ inclisiran, Esperion Therepeutics’ Nexletol and Nexlizet, according to a press release.
Comments on the scoping document will be accepted until 5 p.m. EST July 24.
To read the scoping document, click here.
Click here to read the full press release.